DEC 17, 2016 8:47 AM PST

Deficiency of Two Opposing Enzymes Spurs Liver Cancer

WRITTEN BY: Xuan Pham

If a cancer is caused by the over-activation of proteins that enhance growth, then blocking these enzymes should stunt the tumor. Yet, in liver cancer, drugs that inhibit growth enzymes do not seem to slow the cancer growth. And the most recent research suggests that cancer biology is more complex than previously thought.

"When it comes to liver cancer, I think we've been making strategic mistakes," said Gen-Sheng Feng, professor at the University of California, San Diego, and the study’s senior author. "In cancer development, we always thought about two distinct families of enzymes -- one promotes cancer, one inhibits it.”

Indeed, this line of thinking has led to the creation of drugs that, for the most part, do one or the other. That is, they either block the over-active pro-cancer enzymes or stimulate the activity of anti-cancer proteins. “Many drugs have been developed to block the cancer-promoting pathways, but we and others are now finding that many classical pro-cancer proteins are actually inhibitors,” said Feng. This explains why the intended consequences for anticancer drugs don't always work.

To better understand the mechanism behind why cancer drugs fail in liver cancer, the team honed in on the balance of tumor-suppressor genes versus those that promote tumor growth in a mouse model. They found that mice that lacked both types of proteins are, paradoxically, most susceptible to liver disease and cancer.

In particular, the two opposing cancer proteins were identified as Shp2 and Pten. Shp2 is well-characterized as a tumor-promoting protein, while Pten is a known tumor-suppressing protein. Yet, mice with a loss of both of these proteins had the largest and most prominent tumor formation in the shortest amount of time.

"So the roles of tumor-promoting and tumor-suppressing enzymes are not as simple as we thought," Feng said. "This also explains many unwanted side effects with drugs that target these enzymes. Their consequences can differ depending on cell type."

Feng’s team theorized that loss of the two enzymes triggered uncontrolled inflammation and fibrosis in the liver, which helped promote tumor formation. Interestingly, when they analyzed human liver cancer samples, the team found a similar pattern – those with low or deficient levels of SHP2 and PTEN typically had the poorer prognoses.

"Liver cancer is more complicated than we thought. These pathways, when over-activated, stimulate tumor development, but so does inhibiting them," Feng said. "That's why we can't rush to conclusions like we have in the past. But now that we have a good model that mimics the human pathogenic process and we can use that to work out the mechanisms that lead to liver disease and cancer, and search for novel drug targets."

Additional sources: UC San Diego Health

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 20, 2020
Genetics & Genomics
JAN 20, 2020
Epigenetic Changes Make Breast Cancer Cells Drug Resistant
Researchers have found that changes in the structure of the genome in breast cancer cells can make them resistant to drug therapies.
JAN 24, 2020
Immunology
JAN 24, 2020
Immune "Recycling" Could Improve Cancer Immunotherapy
A natural housekeeping function performed by many cells of the human body, including those in the immune system, is under intense scrutiny for its potentia
FEB 13, 2020
Cancer
FEB 13, 2020
Can Ebola help treat glioblastomas?
You might want to sit down for this. New research published in the Journal of Virology has named a surprising new ally to brain tumors: Ebola. Yes, yo
FEB 23, 2020
Cancer
FEB 23, 2020
Celular aging reexamined
New research published in Genes and Development has identified one of the mysteries of aging. According to scientists at Sanford Burnham Prebys Medical Dis
MAR 23, 2020
Genetics & Genomics
MAR 23, 2020
Diagnosing Cancer by Looking for Microbial DNA in the Blood
Liquid biopsies aim to diagnose a disease with only a bit of biological fluid, usually blood.
MAR 29, 2020
Cancer
MAR 29, 2020
Improving ependymoma diagnostics
Have you ever heard of ependymoma? This rare form of brain cancer most commonly occurs in young children when tumors form from ependymal cells in the brain
Loading Comments...